Close to 80% of people with epilepsy live in low- and middle-income countries, where the treatment gap reaches 90% in the poorest. Average availability of generic antiseizure medicines in the public sector of those countries runs below 50%, while more than 70% of patients could be seizure free on appropriate treatment.
62 of these 181 lines are injectable, covering acute and emergency presentations alongside the extended-release oral range.
Range depth
11 levetiracetam and 6 divalproex presentations.
Oral atypicals across the common maintenance strengths.
10 pregabalin presentations.
11 citicoline presentations.
We establish what is already registered in your market, who supplies it today, and where demand is going unmet.
We set your current range against the portfolio and separate genuine gaps from lines you already stock.
You get the molecules in filing order, which of them need a dossier built for your authority, and which fall outside the range.
We compile the dossier in CTD format for your authority and supply the COPP and plant-level WHO-GMP and PIC/S certificates behind it.
We analyse your market and set your existing range against the portfolio, then return the molecules worth filing in priority order with the documentation route for each.